APIM Therapeutics announces IND for ATX-101 in Ovarian Cancer

Published: Tue May 11 2021

APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer.

The trial will be conducted in Australia, South Korea and Taiwan.

Read APIM Therapeautics press release here